TY - GEN A1 - Jung, Friedrich A1 - Krieger, Volker A1 - Hufert, Frank A1 - Küpper, Jan-Heiner T1 - Herd immunity or suppression strategy to combat COVID-19 T2 - Clinical Hemorheology and Microcirculation N2 - Some months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Some states, such as the Netherlands, Germany, Great Britain, Sweden and the USA initially focused on keeping the restrictions for economy and society as low as possible. The responsible authorities were of the opinion - and still are e.g. in Sweden - that it is sufficient enough to protect particularly vulnerable persons such as the elderly or people with pre-existing conditions. The idea behind this is that as soon as 60 to 70 percent of the population is infected with a pathogen, a so-called “herd immunity” has developed. However, the increasing numbers of deaths and modelling studies showed the expected overload of the hospitals. Therefore, most countries decided for a temporary lockdown with the exception of Sweden. Based on the number of the total population, three times more people died from COVID-19 in Sweden (2679 deaths per 10 million inhabitants) compared to Germany (6848 deaths per 80 million inhabitants). The comparison Sweden versus Taiwan is even worse because 1072 times more people died in Sweden based on the number of the population (6 deaths per 24 million inhabitants). KW - COVID-19 KW - strategy KW - Sweden KW - Taiwan KW - Germany Y1 - 2020 UR - https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch209006 U6 - https://doi.org/10.3233/CH-209006 SN - 1875-8622 SN - 1386-0291 VL - 75 IS - 1 SP - 13 EP - 17 ER - TY - GEN A1 - Küpper, Jan-Heiner A1 - Jung, Friedrich A1 - Krieger, Volker A1 - Hufert, Frank T1 - A comparison of mortality rates between European and Asian States T2 - Clinical Hemorheology and Microcirculation Y1 - 2020 U6 - https://doi.org/10.3233/CH-209008 SN - 1875-8622 SN - 1386-0291 VL - 75 IS - 1 SP - 3 EP - 5 ER - TY - GEN A1 - Jung, Friedrich A1 - Krieger, Volker A1 - Hufert, Frank A1 - Küpper, Jan-Heiner T1 - How we should respond to the Coronavirus SARS-CoV-2 outbreak: A German perspective T2 - Clinical Hemorheology and Microcirculation N2 - BACKGROUND: In the early phase of the COVID-19 pandemic Germany missed to set up efficient containment measures. Consequently, the number of cases increased exponentially until a lockdown was implemented to suppress the spread of SARS-CoV-2. Fortunately, Germany has a high capability for coronavirus lab testing and more than 30,000 ICU beds. These capabilities and the lockdown turned out to be an advantage to combat the pandemic and to prevent a health-system overload. AIM: The aim was to predict the plateau day of SARS-CoV-2 infections or deaths. RESULTS: The effect on the viral spread of the German measures taken and the impact on the peak of new infection cases is shown. By normalizing daily case numbers, the plateau day of the current outbreak in Germany could be calculated to be reached at April 12, 2020 (day 103 of 2020). CONCLUSION: Normalized case number curves are helpful to predict the time point at which no further new infections will occur if the epidemic situation remains stable. Upon reaching the plateau day during a lockdown phase, a residual time-period of about 2-3 weeks can be utilized to prepare a safe unlocking period. As can be learned from Asian countries such as South Korea and Taiwan there must be strict rules to keep the risk of infection low. Those include social distancing, face mask wearing in combination with digital contact tracing and serosurveillance studies. Following those rules, a safe dance around the infection curve allows to keep the population at a reduced infection rate. KW - Corona virus KW - SARS-CoV-2 KW - COVID-19 KW - herd immunity KW - hammer and dance strategy Y1 - 2020 UR - https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch209004 U6 - https://doi.org/10.3233/CH-209004 SN - 1875-8622 SN - 1386-0291 VL - 74 IS - 4 SP - 363 EP - 372 ER -